胃轻瘫安慰剂治疗的反应率与不良事件率:系统评价与荟萃分析
该系统评价与荟萃分析检索至2022年8月2日的随机对照试验,纳入35项胃轻瘫药物试验,评估安慰剂反应率与不良事件率。23项报告复合终点的试验中,汇总安慰剂反应率为29.3%(95%CI 23.7%-35.2%);27项试验中安慰剂不良事件发生率为33.8%(95%CI 26.4%-41.8%)。作者认为未来试验应至少8周、使用验证问卷并区分胃轻瘫亚型。
要点
- 23项试验复合终点汇总安慰剂反应率为29.3%(95%CI 23.7%-35.2%)
- 27项试验安慰剂不良事件发生率为33.8%(95%CI 26.4%-41.8%)
- 特发性胃轻瘫安慰剂反应率34.2% vs 糖尿病胃轻瘫28.1%
核心结论
- 该荟萃分析评估了胃轻瘫药物试验中安慰剂反应率与不良事件率,作者认为未来试验应至少8周、使用验证问卷并区分胃轻瘫亚型以准确评估治疗获益。
研究设计与样本
- 系统评价与荟萃分析,检索至2022年8月2日的医学文献,纳入35项比较活性药物与安慰剂的胃轻瘫随机对照试验。
- 数据按意向性治疗分析提取,脱落者假定为治疗失败;采用随机效应模型汇总,以比例及95%置信区间表示。
主要发现
- 23项报告复合改善终点的试验中,汇总安慰剂反应率为29.3%(95%CI 23.7%-35.2%)。
- 安慰剂反应率在特发性胃轻瘫为34.2% vs 糖尿病胃轻瘫28.1%,未使用验证症状问卷的试验为31.2% vs 27.4%,疗程<4周的随机对照试验为32.6% vs ≥9周23.2%。
- 27项试验中安慰剂组不良事件发生率为33.8%(95%CI 26.4%-41.8%)。
- 安慰剂不良事件在特发性胃轻瘫为17.9% vs 糖尿病胃轻瘫43.4%,疗程<4周为33.7% vs ≥9周40.7%,活性药物与安慰剂随机化比例1:1为26.7% vs 3:1为50.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Multiple drugs have been used to treat gastroparesis symptoms, yet their therapeutic benefits are poorly understood partly due to lack of insight into response and adverse event rates with placebo in randomized controlled trials (RCTs). We evaluated these issues systematically in drug trials for gastroparesis. METHODS: We searched the medical literature through August 2, 2022 to identify RCTs comparing active drug with placebo in patients with gastroparesis. We assessed placebo response rates according to at least one of the following endpoints: improvement according to a composite outcome, nausea, vomiting, abdominal pain, bloating, or fullness, as well as total adverse events, and adverse events leading to withdrawal. We extracted data as intention-to-treat analyses with dropouts assumed to be treatment failures. We pooled placebo response and adverse event rates using a random effects model and expressed as proportions with 95% confidence intervals (CIs). RESULTS: Thirty-five studies were eligible. Among 23 trials reporting a composite endpoint of improvement, the pooled placebo response rate was 29.3% (95% CI, 23.7%-35.2%). Pooled placebo response rates were higher in idiopathic compared with diabetic gastroparesis (34.2% vs 28.1%), among trials that did not use validated symptom questionnaires (31.2% vs 27.4%), and in RCTs of shorter duration (<4 weeks, 32.6% vs ≥9 weeks, 23.2%). Adverse events occurred in 33.8% (95% CI, 26.4%-41.8%) of patients with placebo, in 27 trials, and were less common in idiopathic compared with diabetic gastroparesis (17.9% vs 43.4%), trials of shorter duration (<4 weeks, 33.7% vs ≥9 weeks, 40.7%), and trials with lower randomization ratios of active drug to placebo (1:1, 26.7% vs 3:1, 50.5%). CONCLUSIONS: This meta-analysis assessed placebo response and adverse event rates in gastroparesis. To accurately assess therapeutic gain, future trials should be a minimum of 8 weeks duration, use validated questionnaires, and distinguish gastroparesis subtypes.
引用
- Wise JL, Ingrosso MR, Ianiro G, et al. Response and Adverse Event Rates With Placebo in Gastroparesis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2022. PMID: 36270614. doi:10.1016/j.cgh.2022.09.033
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。